REGENXBIO

Update in progress

RGNX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

REGENXBIO is a clinical‑stage biotechnology company developing gene therapies that deliver functional genes to cells with genetic defects using its NAV Technology Platform, an adeno-associated virus delivery system. Its pipeline includes ABBV-RGX-314 for wet AMD and retinal diseases, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II, and RGX-111 for type I. It licenses NAV and collaborates with AbbVie and Nippon Shinyaku on these programs outside the U.S.

Company score

Sentiment: -0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.04; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive